China Pharma Holdings Inc's Cash & cash equivalent grew by 80.96 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in China Pharma Holdings Inc's Quick Ratio to 0.04, Quick Ratio remained below China Pharma Holdings Inc average.

Within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than China Pharma Holdings Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3957 to 4029.

Explain Quick Ratio?
How much Cash & cash equivalents CPHI�s has?
What are CPHI�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CPHI Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	46.3 %	41.89 %	-6.31 %	39.13 %	11.43 %
Y / Y Cash & cash equivalent Change	-	-	-44.95 %	-	-
Quick Ratio MRQ	0.04	0.02	0.07	0.04	-
CPHI's Total Ranking	# 4029	# 3957	# 4442	# 0	#
Seq. Current Liabilities Change	5.7 %	54.61 %	-29.02 %	26.13 %	2.51 %
Seq. Cash & cash equivalent Change	80.96 %	-51.18 %	28.95 %	-	-

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 431
Healthcare Sector	# 872
Overall Market	# 4029

Quick Ratio Statistics
High	Average	Low
0.6	0.25	0.01
(Dec 31 2023)		(Mar 31 2020)

Financial Statements
China Pharma Holdings Inc's Current Liabilities	$ 8 Millions	Visit CPHI's Balance sheet
China Pharma Holdings Inc's Cash & cash equivalent	$ 0 Millions	Visit CPHI's Balance sheet
Source of CPHI's Sales		Visit CPHI's Sales by Geography

Cumulative China Pharma Holdings Inc's Quick Ratio

CPHI's Quick Ratio for the trailling 12 Months

CPHI Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	30.39 %	21.57 %	7.31 %	10.38 %	-9.4 %
Y / Y Cash & cash equivalent TTM Growth	73.25 %	24.61 %	-2.26 %	-68.32 %	-85.05 %
Quick Ratio TTM	0.04	0.03	0.03	0.04	0.03
Total Ranking TTM	# 4160	# 3993	# 3201	# 0	#
Seq. Current Liabilities TTM Growth	10.2 %	9.89 %	-1.44 %	9.24 %	2.75 %
Seq. Cash & cash equivalent TTM Growth	39.03 %	27.5 %	-31.5 %	42.69 %	0 %

Quick ratio ranking by company, industry and sector >> Back to CPHI Financial Strength Comparisons >> Go to Compare CPHI Quick Ratio to its Competitors

On the trailing twelve months basis CPHI Cash & cash equivalent soared by 80.96 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in China Pharma Holdings Inc's Quick Ratio to 0.04, Quick Ratio remained below CPHI average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than China Pharma Holdings Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3993 to 4160.

Explain Quick Ratio?
How much Cash & cash equivalents CPHI�s has?
What are CPHI�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 916
Within the Market	# 4160

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.46	0.22	0.01
(Jun 30 2016)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Igc Pharma Inc	0.11	$ 0.354 Millions	$ 3.287 Millions
Tuhura Biosciences Inc	0.11	$ 0.996 Millions	$ 9.255 Millions
Gridai Technologies Corp	0.10	$ 1.380 Millions	$ 14.146 Millions
Bioxcel Therapeutics Inc	0.09	$ 12.841 Millions	$ 137.149 Millions
Galectin Therapeutics Inc	0.09	$ 13.275 Millions	$ 151.619 Millions
Lftd Partners Inc	0.08	$ 0.304 Millions	$ 3.648 Millions
Processa Pharmaceuticals Inc	0.08	$ 0.196 Millions	$ 2.387 Millions
Cv Sciences Inc	0.05	$ 0.266 Millions	$ 4.943 Millions
Citius Pharmaceuticals Inc	0.05	$ 17.008 Millions	$ 333.952 Millions
Sunshine Biopharma Inc	0.05	$ 0.281 Millions	$ 5.619 Millions
Hcw Biologics Inc	0.04	$ 0.741 Millions	$ 18.648 Millions
China Pharma Holdings Inc	0.04	$ 0.305 Millions	$ 7.682 Millions
Bioxytran Inc	0.03	$ 0.177 Millions	$ 5.275 Millions
Cdt Equity Inc	0.03	$ 0.700 Millions	$ 23.351 Millions
Shuttle Pharmaceuticals Holdings Inc	0.03	$ 0.102 Millions	$ 3.481 Millions
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions
Os Therapies Incorporated	0.01	$ 0.205 Millions	$ 20.653 Millions
The Greater Cannabis Company Inc	0.01	$ 0.000 Millions	$ 0.012 Millions
Chemocentryx Inc.	0.01	$ 1.253 Millions	$ 139.868 Millions
NIKA PHARMACEUTICALS, INC	0.01	$ 0.003 Millions	$ 0.341 Millions
Evofem Biosciences Inc	0.01	$ 0.714 Millions	$ 88.615 Millions

Date modified: 2026-09-12T06:18:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.